Feedback / Questions
vobarilizumab (ALX-0061) - Sanofi
ALX0061 interim P2 results
(Ablynx)
-
Oct 5, 2012 -
P2, N=72; NCT01284569; Consistent reduction of disease activity across all dose levels; DAS28 remission up to 60%
P2 data
•
Rheumatoid Arthritis
http://www.larvolonline.com/tlg/ccdb/AblynxALX0061InterimP2resultsOct042012.pdf
Oct 5, 2012
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.